Journal: iScience

Article Title: A method for expressing two proteins at a tunable ratio allows for studying the kinetics of creatine transport by MCT12

doi: 10.1016/j.isci.2026.117719

Figure Lengend Snippet:

Article Snippet: pCMV-VSV-G , Addgene , Cat # 8454.

Techniques: Cell-Signaling, Virus, Recombinant, Clinical Proteomics, Membrane, Staining, Cloning, Software

Journal: Cancer Communications

Article Title: Targeting TREM2 + and TIMD4 + Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma

doi: 10.34133/cancomm.0056

Figure Lengend Snippet: Targeting Trem2 and Timd4 to enhance anti-Pd-1 efficacy in ICC. (A) Workflow diagram of the anti-Csf1r antibody treatment in Kras-P19-induced ICC mouse models. After 6 doses of treatment, tumor tissues were collected for bulk RNA-seq. (B and C) Morphology of tumors in anti-Csf1r antibody treated versus control groups ( ** P < 0.01; Mann–Whitney U test). (D and E) Survival curves (Kaplan–Meier) of Yap-Akt-induced and Kras-P19-induced ICC mice treated with anti-Csf1r antibody versus controls. (F) Proportions of Trem2 + macrophages among total macrophages in tumor tissues from anti-Csf1r antibody-treated and control mice following 6 anti-Csf1r antibody treatments, as determined by flow cytometry ( **** P < 0.0001; Mann–Whitney U test). (G) Cd8 + and Cd11b + cell ratios in anti-Csf1r antibody treated versus control mice (the proportion of target cells among total leukocytes; *** P < 0.001; **** P < 0.0001; Mann–Whitney U test). (H and I) Volcano plot (H) and GO enrichment (I) of DEGs in anti-Csf1r antibody treated tumors. (J) Workflow of therapeutic in Yap-Akt-induced ICC mice. One hundred C57BL/6 mice were used to establish ICC model via hydrodynamic tail vein injection of the Yap-Akt-SB100 plasmid. On day 7, tumor burden was assessed using IVIS optical imaging. Forty-eight mice with comparable total fluorescence values were selected and evenly randomized into 8 groups, ensuring no statistically significant difference in initial tumor burden among groups. The mice were then treated every 3 days for a total of 6 times. Two days after the final treatment, the mice were fasted for 6 h before tumor tissues were harvested for flow cytometric analysis. (K and L) Tumor morphology and the liver weight across treatment groups. (M to O) Flow cytometric analysis of tumor-infiltrating immune-cell populations in mice treated with isotype control, anti-Trem2, anti-Timd4, anti-Pd-1, anti-Trem2 plus anti-Pd-1, anti-Timd4 plus anti-Pd-1, anti-Trem2 plus anti-Timd4, or anti-Trem2 plus anti-Timd4 and anti-Pd-1 antibodies, as indicated in (J). (M) Proportion of Cd45 + Cd8 + T cells among total Cd45 + cells. (N) Proportion of Pd-1 + cells among Cd8 + T cells. (O) Proportion of Foxp3 + cells among Cd4 + T cells. Healthy mice were included as a reference group ( * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant; one-way ANOVA followed by Tukey’s multiple-comparisons test). (P) Survival curves (Kaplan–Meier) of Kras-p19-induced ICC mice under therapeutic interventions. Abbreviations: ICC, intrahepatic cholangiocarcinoma; GO, Gene Ontology; DEG, differentially expressed gene; SB100, Sleeping beauty transposon 100.

Article Snippet: For the Kras-P19 model, plasmids pCaggs-KRAS G12D (20 μg; provided by Prof. Lei Wang of Nanjing Drum Tower Hospital), CRISPR/Cas9 sg-p19 (pX330-sg-p19, 15 μg; provided by Prof. Lei Wang of Nanjing Drum Tower Hospital), and SB100 (3 μg; catalog no. 34879, Addgene) in 2 ml of saline were hydrodynamically injected.

Techniques: RNA Sequencing, Morphology, Control, MANN-WHITNEY, Flow Cytometry, Injection, Plasmid Preparation, Optical Imaging, Fluorescence, Analysis, Immune Cell